Trial Profile
Inhibition of liver cystogene
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Polycystic kidney disease; Polycystic liver disease
- Focus Therapeutic Use
- Acronyms TVP for PKLD
- 15 Mar 2019 Status changed from not yet recruiting to recruiting.
- 04 Oct 2017 New trial record